Sanofi’s new CEO has identified dupixent and vaccines as the mid-term growth drivers, as the company moves away from slow-growing diabetes and cardiovascular therapeutic areas. Consumer Healthcare and other non-core assets should soon be up for sale and the proceeds could be diverted towards fast-growing therapeutic areas (it acquired an immune-oncology drug recently). With respect to profitability, the recently introduced €2bn cost savings programme holds the key. With a strategy
19 Dec 2019
New CEO sets aggressive yet achievable targets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New CEO sets aggressive yet achievable targets
Sanofi (SANO:WBO) | 0 0 1.3% | Mkt Cap: 81,283m
- Published:
19 Dec 2019 -
Author:
Rishabh Kochar -
Pages:
4
Sanofi’s new CEO has identified dupixent and vaccines as the mid-term growth drivers, as the company moves away from slow-growing diabetes and cardiovascular therapeutic areas. Consumer Healthcare and other non-core assets should soon be up for sale and the proceeds could be diverted towards fast-growing therapeutic areas (it acquired an immune-oncology drug recently). With respect to profitability, the recently introduced €2bn cost savings programme holds the key. With a strategy